He or Ho: No laughing matter

With new Phase III data fueling uncertainty over whether mipomersen is approvable beyond a niche application for cholesterol control, and what additional testing might be needed to get there, investors drove down the price of Isis Pharmaceuticals Inc. (NASDAQ:ISIS) by $2.06 (19%) to $8.98 last Tuesday.

Shares of partner Genzyme Corp. (NASDAQ:GENZ) were off $0.37 on the day to $54.50...